TELO

+ Watchlist + Portfolio

Telomir Pharmaceuticals, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.17
52-Week Range: $0.89 – $2.09
Market Cap: $81.15M
P/E (TTM): —
EPS (TTM): -1.11
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 8.19
PEG Ratio: —
Return on Equity: -213.10%
Return on Assets: -122.81%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 16.14
Debt/Equity: 0.03
Total Debt: $136.90K
Free Cash Flow: $-3.07M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $76.12M

TELO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$833.21K	$1.57M	$2.24M	$2.44M
Selling, General & Admin	$20.94K	$600.19K	$9.64M	$8.10M
Operating Expenses	$854.15K	$3.94M	$12.24M	$10.54M
Operating Income	-$854.15K	-$3.94M	-$12.24M	-$10.54M
EBITDA	-$854.15K	-$11.43M	-$12.19M	-$10.41M
Pretax Income	-$854.15K	-$13.07M	-$16.53M	-$10.41M
Net Income	-$854.15K	-$13.07M	-$16.53M	-$10.41M
Diluted EPS	-0.03	-0.44	-0.56	-0.33
Diluted Shares	29.61M	29.61M	29.54M	31.65M

TELO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.42K	$1.23K	$1.27M	$7.29M
Receivables	$0.00	$130.00K	$0.00	—
Current Assets	$48.73K	$435.23K	$1.32M	$7.34M
Total Assets	$48.73K	$4.77M	$1.32M	$7.34M
Current Liabilities	$986.01K	$1.34M	$680.97K	$1.43M
Total Debt	—	$101.00K	—	—
Total Liabilities	$986.01K	$1.34M	$680.97K	$1.43M
Retained Earnings	-$992.28K	-$14.06M	-$30.60M	-$41.01M
Shareholders' Equity	-$937.28K	$3.44M	$643.04K	$5.91M
Working Capital	-$937.28K	-$900.34K	$643.04K	$5.91M
Net Debt	—	$99.77K	—	—

TELO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$468.66K	-$3.86M	-$5.07M	-$3.69M
Free Cash Flow	-$468.66K	-$3.86M	-$5.07M	-$3.69M
Stock-Based Compensation	—	$0.00	$6.87M	$6.13M
Financing Cash Flow	$470.08K	$3.86M	$6.34M	$9.71M
Net Change in Cash	$1.42K	-$188.00	$1.26M	$6.02M

TELO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$337.00K	$42.84K	$759.52K	$1.30M	$467.80K	$444.67K
Selling, General & Admin	$1.85M	$5.03M	$386.95K	$838.47K	$573.54K	$1.32M
Operating Expenses	$2.19M	$5.07M	$1.15M	$2.13M	$1.04M	$1.76M
Operating Income	-$2.19M	-$5.07M	-$1.15M	-$2.13M	-$1.04M	-$1.76M
EBITDA	-$2.18M	-$5.07M	-$1.10M	-$2.06M	-$989.69K	-$1.72M
Pretax Income	-$2.18M	-$5.07M	-$1.10M	-$2.06M	-$990.95K	-$1.72M
Net Income	-$2.18M	-$5.07M	-$1.10M	-$2.06M	-$990.95K	-$1.72M
Diluted EPS	-0.07	-0.17	-0.03	—	-0.03	-0.79
Diluted Shares	29.76M	30.01M	32.40M	—	34.38M	60.84M

TELO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$403.00K	$754.32K	$7.33M	$7.29M	$5.56M	$5.17M
Current Assets	$491.19K	$829.61K	$7.40M	$7.34M	$5.79M	$5.37M
Total Assets	$491.19K	$829.61K	$7.40M	$7.34M	$5.79M	$5.37M
Current Liabilities	$652.29K	$348.39K	$422.81K	$1.43M	$827.31K	$332.42K
Total Liabilities	$652.29K	$348.39K	$422.81K	$1.43M	$827.31K	$332.42K
Retained Earnings	-$32.78M	-$37.85M	-$38.95M	-$41.01M	-$42.00M	-$43.72M
Shareholders' Equity	-$161.11K	$481.22K	$6.98M	$5.91M	$4.96M	$5.03M
Working Capital	-$161.11K	$481.22K	$6.98M	$5.91M	$4.96M	$5.03M

TELO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$863.13K	-$696.45K	-$927.26K	-$1.20M	-$1.77M	-$1.01M
Free Cash Flow	-$863.13K	-$696.45K	-$927.26K	-$1.20M	-$1.77M	-$1.01M
Stock-Based Compensation	$1.38M	$4.66M	-$741.86K	$832.05K	$39.80K	$786.47K
Financing Cash Flow	$0.00	$1.05M	$7.50M	$1.16M	$47.35K	$622.11K
Net Change in Cash	-$863.13K	$351.32K	$6.57M	-$42.63K	-$1.73M	-$390.23K

Market Snapshot

About

Telomir Pharmaceuticals, Inc. is a biotechnology company focused on developing therapeutics to extend healthspan by addressing cellular aging and age-related diseases. The company is researching compounds that may influence telomere biology and cellular senescence. Telomir aims to develop treatments for conditions associated with aging and metabolic dysfunction.